FDA tells GLP-1 makers to warn of potential vision loss side effect

FDA has directed manufacturers of GLP‑1 drugs such as Ozempic and Wegovy to add warnings about a potential increased risk of eye stroke, a rare condition known as non‑arteritic anterior ischemic optic neuropathy (NAION) that can lead to vision loss or blindness. The agency requires the warnings to inform both patients and healthcare providers of this serious side effect.